Citations

Clear

17 citation(s) found for "Hsu, Cheng-En".

The Impact of Capitate Morphology on Scaphoid Flexion in Wrist Kinematics
Hsu, Cheng-En , Vilai, Parunyu , Wan, Rou , Zhao, Chunfeng , Moran, Steven L., Moran, Steven L.

Mayo Clinic

Journal of Wrist Surgery | January 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2772-1602 Get It

Abstract Column-type wrists, which exhibit increased scaphoid flexion during radial deviation, often experience greater loss of motion after periscaphoid arthrodesis compared with row-type wrists. Dynamic radiographic series are typically used to differentiate these kinematic patterns. In this study, we evaluate capitate morphology as a means of predicting column- or row-type carpal kinematics. This study investigated whether wrist kinematic patterns could be predicted using simple anteroposterior (AP) radiographs. We hypothesized that capitate morphology, given its close articulation with the scaphoid, influences these patterns. We analyzed 75 wrist motion radiographic series from 45 patients. Capitates were classified as either Type I (rectangular) or Type II (pentagonal) based on their shape. Wrist kinematic patterns were categorized as row- or column-type based on the degree of scaphoid length shortening during radial deviation. Our analysis revealed that a Type II capitate was a significant predictor of column-type wrists, with an odds ratio of 6.01 compared with Type I (p = 0.014). Furthermore, Type II capitates were associated with increased scaphoid flexion and reduced translation. Capitate morphology, as assessed from a plain AP radiograph, can serve as an easily accessible marker and reliable predictor of wrist motion patterns. This could potentially aid in surgical planning and patient counseling, particularly when dynamic radiographic series are not feasible. Diagnostic, Level III.
Capitate morphology as a risk factor for healing in scaphoid non-union
Hsu, Cheng-En , Vilai, Parunyu, Wan, Rou , Moran, Steven L. , Moran, Steven L , Vilai, Parunyu , Zhao, Chunfeng

Mayo Clinic

Journal of Hand Surgery (European Volume) | December 8, 2025 | Volume: 51 | Issue: 4 | Pages: 428-437

10.1177/17531934251399509 | PMID 41355072 Get It

Introduction: This study investigated the association between capitate morphology and the success rates of non-vascularized bone graft (NVBG) and vascularized bone graft (VBG) operations for scaphoid nonunion. Methods: We retrospectively analysed 213 patients with established scaphoid non-union who underwent either non-vascularized bone graft ( n = 75) or vascularized bone graft ( n = 138). We analysed risk factors, including demographics, medical history, implant type, previous surgery, bone graft donor site and capitate morphology for their association with treatment outcome. We also assessed the relationship between capitate and scaphoid morphology in the uninjured wrists of 31 patients. Results: The overall success rate was 81% for NVBG and 86% for VBG, with no significant difference. For NVBG, Type II capitate, age 40 or older and tobacco use were significant risk factors for failure. For VBG, only previous surgery was a significant risk factor. In uninjured wrists, a Type II capitate was associated with a significantly thinner scaphoid waist and a lower waist index than a Type I capitate. Conclusion: Our study introduces a new radiographic classification of capitate morphology and establishes its significant association with scaphoid morphology. Beyond traditional factors, capitate morphology can help to assess scaphoid morphology and potentially infer vascularity, aiding the selection of the most appropriate bone graft type for treating scaphoid non-union. Level of evidence: III
Capitate Morphology: A New Radiographic Association with Preiser's Disease
Hsu, Cheng-En , Vilai, Parunyu , Wan, Rou , Zhao, Chunfeng , Moran, Steven L.

Mayo Clinic

Journal of Wrist Surgery | December 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2745-8586 Get It

Abstract Preiser's disease (PD), or idiopathic avascular necrosis of the scaphoid, is a debilitating condition leading to wrist pain, dysfunction, and pan-carpal arthritis. While impaired scaphoid vascularity is central to its pathogenesis, identifying individuals at risk is challenging due to the morphological distortion of the scaphoid as the disease progresses. This study aims to investigate the association between a novel capitate morphology classification, scaphoid morphology, and their impact on PD prevalence and characteristics. We also re-evaluate negative ulnar variance (NUV) as a potential risk factor for PD. This retrospective case–control study included 34 PD patients and 340 age-matched controls. Capitate morphology was classified into Type I/II on anteroposterior (AP) radiographs based on capitotrapezoid–scaphocapitate (CT–SC) joint line angle and ratio. Scaphoid morphology was assessed via the waist index on contralateral healthy wrists. Radiographic measurements of ulnar variance and PD staging were also performed. Statistical analyses compared morphological prevalence and risk factors between groups. Type II capitate was significantly more prevalent in the PD group (35.3%) than in controls (17.1%, p = 0.018). Similarly, NUV was significantly higher in PD patients (29%) compared with controls (6.8%, p < 0.001). We found a strong correlation between Type II capitate and slender (Type II) scaphoid morphology in healthy wrists. No significant differences in age, gender, or affected side were observed. Interobserver and intraobserver agreements for capitate classification were substantial (kappa ≥0.882). Our study introduces a reliable radiographic method for classifying capitate morphology, which strongly correlates with intrinsic scaphoid shape and potential vascular vulnerability. Both Type II capitate morphology and NUV are significant predisposing factors for PD. These findings offer valuable insights for identifying at-risk individuals and improving understanding of PD's multifactorial etiology. Diagnostic Level III.
Surgical treatment of inferior pole fractures of the patella: a systematic review
Chang, Chih‐Hsun, Kuan, Fa‐Chuan , Hong, Chih‐Kai , Su, Wei‐Ren, Hsu, Kai‐Lan , Hsu, Kai-Lan , Shih, Chien‐An , Su, Wei‐Ren

Mayo Clinic

Journal of Experimental Orthopaedics | June 1, 2023 | Volume: 10 | Issue: 1 | Pages: No page available

10.1186/s40634-023-00622-y | PMID 37261559 Get It

AbstractPurposeThis study aimed to comprehensively review the existing evidence concerning surgical treatment of inferior pole fractures of the patella and to report the outcomes and complications of different fixation techniques.MethodThis systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Searches of PubMed, Scopus, and Web of Science were conducted in March 2023. Studies were screened against predecided inclusion and exclusion criteria. The extracted data included fracture characteristics, surgical techniques, and radiographic and functional outcomes. The Methodological Index for Non‐Randomized Studies (MINORS) quality assessment tool was used to assess the eligible literature. The primary outcome was postoperative range of motion of different surgical methods, and the secondary outcomes were other clinical results and complications.ResultsA total of 42 studies satisfied all the inclusion criteria and were deemed suitable for review. Fourteen case–control studies and 28 case series were selected, for a total of 1382 patients with a mean age of 51.0 years (range = 11–90). The follow‐up period ranged from 6 to 300 months. The surgical techniques were categorized based on the device used as follows: (1) rigid fixation device; (2) tensile fixation device; (3) mixed device; and (4) extra‐patella device.ConclusionRegarding the outcomes following surgical treatment of inferior pole fractures of the patella, the postoperative range of motion (ROM) of each technique ranged from 120° to 135°, with the exception of that involving the patellotibial wire which had poorer outcomes. The lowest functional score was also found in those using the patellotibial wire. Complications after surgery are rare, but approximately half of the patients required additional surgery for implant removal, particularly those whose initial surgery involved rigid fixation devices. It's worth noting that bony fragment excision is no longer recommended, and the combined use of multiple surgical devices is now more common.
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing‐off of erenumab within monthly treatment cycle
Dodick, David W. , Blumenfeld, Andrew , Singh, Rashmi B. Halker , Hsu, Cheng‐Pang, Peng, Cheng , Snellman, Josefin , Chehrenama, Mahan, Blumenfeld, Andrew M , Halker Singh, Rashmi B , Ailani, Jessica , Dodick, David W , Williams, Rachel , Zhang, Feng , Chen, Po‐Wei , Ailani, Jessica

Mayo Clinic

Headache: The Journal of Head and Face Pain | October 13, 2022 | Volume: 63 | Issue: 2 | Pages: 233-242

10.1111/head.14403 | PMID 36226464 Get It

Abstract Background Treatment wearing‐off has been reported for calcitonin gene‐related peptide‐pathway monoclonal antibodies, including erenumab, specifically in the last week of the monthly dosing cycle. Objective We sought to determine the consistency of erenumab effect throughout the monthly treatment cycle. Methods In this post hoc analysis of four pivotal double‐blind, randomized controlled studies of erenumab in episodic and chronic migraine, we assessed wearing‐off based on change in weekly migraine days at week 4 versus average over weeks 1–3 in each monthly dosing cycle. Analyses were conducted at each monthly dosing cycle in all patients, in responders (≥50% reduction in weekly migraine days), and in consistent responders (response in ≥2monthly cycles). Results There was no evidence of wearing‐off in the full study populations of two global studies (N = 946 and N = 656) and two Japan studies (N = 475 and N = 261). In the full study population, mean change in weekly migraine days at week 4 compared with the average over week 1–3 ranged from 0.15 days improvement to 0.19 days worsening in the placebo group and 0.08 days improvement to 0.20 days worsening in the erenumab groups. A subgroup of responders experienced wearing‐off, but the extent of wearing‐off did not differ between erenumab and placebo groups. The mean change in weekly migraine days at week 4 compared with the average over weeks 1–3 ranged from 0.34 to 0.61 days worsening in the placebo group and 0.27 to 0.78 days worsening in the erenumab groups. Few patients had persistent wearing‐off in ≥2 consecutive monthly treatment cycles. For erenumab‐treated responders, serum erenumab concentrations were similar among patients experiencing wearing‐off and those maintaining response. Conclusion No systematic wearing‐off with erenumab was identified. Further research is needed to determine if wearing‐off reported for some patients in clinical practice reflects a true treatment response pattern or normal fluctuations in migraine frequency.
A Stepwise Approach to the “Frozen Neck” for Secondary Microsurgical Reconstruction
Chicco, Maria , Huang, Tony Chieh‐Ting , Lee, Min‐Min , Cheng, Hsu-Tang

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | October 7, 2021 | Volume: 9 | Issue: 10 | Pages: e3841

10.1097/gox.0000000000003841 | PMID 34616642 Get It

Reconstruction of an Octogenarian Major Pretibial Degloving Injury Utilizing Negative Pressure Wound Therapy and Subsequently Combining Fenestrated-Type Artificial Dermis Without Skin Grafting
Hung, Wei-Chung, Chicco, Maria , Huang, Tony Chieh‐Ting , Cheng, Hsu‐Tang , Cheng, Hsu-Tang , Hung, Wei-Chung

Mayo Clinic

The International Journal of Lower Extremity Wounds | March 9, 2021 | Volume: 22 | Issue: 1 | Pages: 210-212

10.1177/1534734620983251 | PMID 33686897 Get It

Major pretibial degloving injuries are complex wounds, which can be challenging to treat. Despite recent advances in reconstructive options, most of these injuries still require a prolonged healing period and may result in amputation. Few reports have been published on the management of these complex traumatic injuries. In this article, we present a case of an octogenarian, frail patient with a major pretibial degloving injury. Treatment included serial surgical debridements in combination with negative pressure wound therapy aimed at salvaging the avulsed tissue. Subsequently, a fenestrated-type artificial dermis and negative pressure wound therapy were used as combined therapy so as to obtain adequate soft tissue coverage. The patient made an unremarkable recovery and was discharged on day 22 after injury. The wound healed by secondary intention without need for skin grafting.
Mortality Within 30 Days After Head and Neck Free Flap Reconstruction: A Systematic Review
Chicco, Maria , Huang, Tony Chieh‐Ting , Cheng, Hsu-Tang

Mayo Clinic

Journal of Craniofacial Surgery | February 26, 2021 | Volume: 32 | Issue: 5 | Pages: 1738-1741

10.1097/scs.0000000000007548 | PMID 34081420 Get It

Objective: The aim of this systematic review is to analyze the 30-day postoperative mortality in patients undergoing free flap reconstruction for head and neck cancer published in literature and to identify associated factors. Methods: The authors performed a literature search between January 1950 and February 2020 in PubMed, EMBASE, and Scopus, using a combination of Medical Subject Headings headings and text keywords related to head and neck cancer; microsurgery or free flap reconstruction; and 30-day mortality. Inclusion criteria were: original studies in English reporting on 30-day mortality after head and neck free flap reconstruction in adult population. Results: Thirty-one publications reported on a total of 13,447 patients who underwent head and neck free flap reconstruction. The published 30-day postoperative mortality ranged from 0% to 6.3%, with an average of 1.21%. A number of studies examined the association between mortality and body mass index, American Society of Anesthesiologists, and comorbidity score and age. One study found that underweight patients had significantly higher mortality. Two studies found no association between the American Society of Anesthesiologists score and 30-day postoperative mortality; however, 1 study reported significantly higher mortality with increased comorbidity score. Regarding association with age, 3 studies found significant higher mortality in older patients, while 5 studies found no difference. Conclusions: The average 30-day postoperative mortality in patients undergoing head and neck free flap reconstruction is 1.21% and is; therefore, not negligible. Careful patient selection and preoperative optimization are essential in order to reduce mortality in head neck free flap reconstruction.
Negative-Pressure Wound Therapy in the Prevention and Management of Complications From Prosthetic Breast Reconstruction
Chicco, Maria , Huang, Tony Chieh‐Ting , Cheng, Hsu-Tang

Mayo Clinic

Annals of Plastic Surgery | February 25, 2021 | Volume: 87 | Issue: 4 | Pages: 478-483

10.1097/sap.0000000000002722 | PMID 34060773 Get It

Background Complications from prosthetic breast reconstruction are distressing for patients, and their management is challenging. For decades, negative-pressure wound therapy (NPWT) has been successfully used for the closure of complex wounds. This study analyzes the outcomes of NPWT use in the prevention and management of complications from prosthetic breast reconstruction. Method A systematic search of studies published until August 2020 was conducted using the PubMed/MEDLINE, EMBASE, and Ebscohost/CINAHL databases and using the following key words: “negative-pressure wound therapy,” “breast reconstruction,” and “prosthesis” (including breast implants and tissue expanders). Analyzed endpoints were outcomes of NPWT use in prosthetic breast reconstruction compared with conventional dressings. The methodological quality of included studies was assessed independently. Comparative studies were further meta-analyzed to obtain pooled odds ratios (ORs) describing the effectiveness of NPWT in prosthetic breast reconstruction. Results/Discussion Ten studies were included with a total of 787 patients (1230 breasts) undergoing prosthetic breast reconstruction with breast implants or tissue expanders. Three case-control studies focused on preventing breast wound complications. The meta-analysis of the 3 studies included 502 breasts receiving NPWT and 698 breasts receiving conventional wound care. The meta-analysis favored NPWT for less mastectomy flap necrosis (5.6% vs 14.3%; OR, 0.46; 95% confidence interval, 0.27 –0.77; P = 0.004; I 2 = 0%) and less overall wound complications (10.6% vs 21.1%; OR, 0.49; 95% confidence interval, 0.35–0.70; P < 0.00001; I 2 = 0%). In the management of nipple-areolar complex venous congestion, 1 case report demonstrated 85% rescue of nipple-areolar complex after using NPWT (−75 mm Hg) for a total of 12 days. In the management of periprosthetic infections, 2 case series used NPWT with instillation. It accelerated the treatment of infection and maintained the breast cavity for future reconstruction. Conventional NPWT also showed good salvage outcome in four studies. Conclusions Current evidence suggests that prophylactic use of NPWT in prosthetic breast reconstruction reduces the rate of overall wound complications and mastectomy flap necrosis. In the management of complications from prosthetic breast reconstructions, NPWT may be a promising option showing beneficial results. Additional high-quality trials are warranted to corroborate the findings of this systematic review.
LCC18, a benzamide‐linked small molecule, ameliorates IgA nephropathy in mice
Yang, Shin‐Ruen , Takahata, Akiko, Wu, Chung‐Yao, Chiu, Hsiao‐Wen, Chen, Cheng‐Hsu , Suzuki, Yusuke , Ka, Shuk‐Man , Huang, Hsu‐Shan , Chen, Ann , Chen, Ann , Huang, Hsu-Shan , Hua, Kuo‐Feng , Wu, Chung-Yao, Hsieh, Chih‐Yu , Mukhopadhyay, Debabrata

Mayo Clinic

The Journal of Pathology | December 29, 2020 | Volume: 253 | Issue: 4 | Pages: 427-441

10.1002/path.5609 | PMID 33373038 Get It

AbstractIgA nephropathy (IgAN), an immune complex‐mediated process and the most common primary glomerulonephritis, can progress to end‐stage renal disease in up to 40% of patients. Accordingly, a therapeutic strategy targeting a specific molecular pathway is urgently warranted. Aided by structure characterisation and target identification, we predicted that a novel ring‐fused 6‐(2,4‐difluorophenyl)‐3‐(3‐(trifluoromethyl)phenyl)‐2H‐benzo[e][1,3]oxazine‐2,4(3H)‐dione (LCC18) targets the NLRP3 inflammasome, which participates in IgAN pathogenesis. We further developed biomarkers for the disease. We used two complementary IgAN models in C57BL/6 mice, involving TEPC‐15 hybridoma‐derived IgA, and in gddY mice. Moreover, we created specific cell models to validate therapeutic effects of LCC18 on IgAN and to explain its underlying mechanisms. IgAN mice benefited significantly from treatment with LCC18, showing dramatically improved renal function, including greatly reduced proteinuria and renal pathology. Mechanistic studies showed that the mode of action specifically involved: (1) blocking of the MAPKs/COX‐2 axis‐mediated priming of the NLRP3 inflammasome; (2) inhibition of ASC oligomerisation and NLRP3 inflammasome assembly by inhibiting NLRP3 binding to PKR, NEK7 and ASC; and (3) activation of autophagy. LCC18 exerts therapeutic effects on murine IgAN by differentially regulating NLRP3 inflammasome activation and autophagy induction, suggesting this new compound as a promising drug candidate to treat IgAN. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.